Patent Term Adjustment vs Patent Term Extension: Key Differences
Patent Term Adjustment (PTA) and Patent Term Extension (PTE) are two distinct mechanisms for extending a US patent's enforceable life, but they serve different purposes and apply to different situations. PTA, under 35 U.S.C. § 154(b), compensates patent applicants for delays caused by the USPTO during prosecution. PTE, under 35 U.S.C. § 156, compensates patent holders for time lost during FDA regulatory review of products like drugs and medical devices. PTA is calculated automatically by the USPTO and applies to virtually any utility patent. PTE must be separately applied for, applies only to FDA-regulated products, and is subject to its own complex calculation.
Need the step-by-step PTE math? Full PTE calculation guide →
Key takeaway
| PTA (§ 154) | PTE (§ 156) | |
|---|---|---|
| Purpose | Compensate for USPTO delays | Compensate for FDA delays |
| Applies to | Any utility patent | FDA-regulated products only |
| Automatic? | Yes (calculated by USPTO) | No (requires separate application) |
| Max extension | No statutory cap | 5 years maximum |
Scope: This article compares PTA and PTE under current US patent law. All examples assume the 20-year-from-filing term framework for utility patents. PTE calculations involve FDA timing data that is beyond the scope of this guide.
What Is Patent Term Adjustment (PTA)?
PTA, codified at 35 U.S.C. § 154(b), adds days to a patent's term to compensate the applicant for delays caused by the USPTO during prosecution. The USPTO calculates PTA automatically and prints it on the face of the patent. PTA is composed of three categories:
A Delay (14/4/4/4 Guarantee)
The USPTO guarantees it will take certain actions within specified timeframes. If it fails, each day of delay is added as A Delay:
- Issue a first Office Action within 14 months of the filing date.
- Respond to applicant replies within 4 months.
- Act on an allowed application within 4 months.
- Issue a patent within 4 months of paying the issue fee.
B Delay (3-Year Guarantee)
If the USPTO does not issue a patent within 3 years of the actual filing date (excluding certain periods such as RCE-related delays and applicant-requested delays), each additional day is counted as B Delay.
C Delay (Interference, Secrecy Orders, Appeal)
C Delay compensates for delays due to interference or derivation proceedings, secrecy orders, or successful appeals to the Patent Trial and Appeal Board (PTAB) or the Federal Circuit.
The PTA Formula
The total PTA = A + B + C − overlap between A and B − applicant delay. Applicant delay includes things like filing late responses, requesting extensions of time, or filing supplemental replies. The USPTO provides a detailed breakdown in each patent's PTA calculation (see MPEP § 2730).
What Is Patent Term Extension (PTE)?
PTE, codified at 35 U.S.C. § 156, extends a patent's term to compensate for time spent in regulatory review before the patented product could be commercially marketed. PTE applies to:
- Drug products (new drug applications under the FDCA)
- Medical devices (premarket approval applications)
- Biologics (approved through a Biologics License Application)
- Food and color additives (subject to premarket approval)
PTE must be applied for by the patent owner within 60 days after FDA approval. The extension is calculated based on the regulatory review period (time from IND filing to NDA approval, for drugs) and is subject to a maximum of 5 years. The total remaining patent term after the extension cannot exceed 14 years from the date of FDA approval.
Side-by-Side Comparison
| Feature | PTA (§ 154(b)) | PTE (§ 156) |
|---|---|---|
| Legal basis | 35 U.S.C. § 154(b) | 35 U.S.C. § 156 |
| Purpose | Compensate for USPTO prosecution delays | Compensate for FDA regulatory review delays |
| Who benefits | Any utility patent applicant | Holders of patents on FDA-regulated products |
| How applied | Automatically calculated by USPTO | Requires separate application within 60 days of approval |
| Maximum extension | No statutory maximum (depends on delays) | 5 years; total post-approval term cannot exceed 14 years |
| Measurement unit | Days | Days (half the testing phase + full approval phase) |
| Listed on patent face | Yes | Published separately in the Federal Register & Orange Book |
Why Our Calculator Includes PTA but Not PTE
Our Patent Expiration Calculator automatically computes PTA because it is available from USPTO data for every patent and can be applied algorithmically. PTE, on the other hand, requires product-specific FDA approval data, applies to a small subset of patents, and involves regulatory timing calculations that go beyond standard patent data. We clearly note when a patent may have a PTE so users know to investigate further.
Worked Example: Patent with 206 Days of PTA
Worked example
Patent: US 10,123,456 (hypothetical)
- Earliest effective filing date: January 15, 2015 (standalone application, no parent).
- Base expiration: January 15, 2015 + 20 years = January 15, 2035.
- PTA breakdown:
- A Delay: 120 days
- B Delay: 150 days
- C Delay: 0 days
- Overlap (A ∩ B): 34 days
- Applicant delay: 30 days
- Total PTA: 120 + 150 + 0 − 34 − 30 = 206 days
- PTA-adjusted expiration: January 15, 2035 + 206 days = August 9, 2035.
- Terminal disclaimer check: No TD filed. Final expiration: August 9, 2035.
Brief Overview of PTE: Which Products Qualify
PTE is available for the first commercial marketing of a new product that required FDA premarket regulatory review. The key categories include:
- New drugs: Approved through a New Drug Application (NDA) under the Federal Food, Drug, and Cosmetic Act. These patents are listed in the FDA Orange Book.
- Medical devices: Approved through a Premarket Approval Application (PMA).
- Biologics: Approved through a Biologics License Application (BLA).
- Food and color additives: Subject to premarket approval.
Only one patent per product approval can receive a PTE, and the patent must claim either the product itself, a method of using the product, or a method of manufacturing the product.
Can a Patent Receive Both PTA and PTE?
Yes. A patent can receive both PTA (for USPTO prosecution delays) and PTE (for FDA regulatory delays). The two adjustments are independent: PTA is added first based on prosecution delays, and PTE extends the resulting term further based on the regulatory review period. However, the total effective extension under PTE is calculated based on the regulatory review period and is still subject to the 5-year cap and the 14-year post-approval limit.
In practice, a pharmaceutical patent might have, for example, 200 days of PTA and 3 years of PTE, resulting in a significantly extended patent life. This is particularly common for blockbuster drugs where the FDA approval process is lengthy.
Frequently asked questions
Yes. PTA (for USPTO prosecution delays) and PTE (for FDA regulatory delays) are independent. PTA is added first, based on prosecution delays, and PTE extends the resulting term further based on the regulatory review period, subject to the 5-year cap and the 14-year post-approval limit.
No. PTA is calculated automatically by the USPTO and printed on the face of the patent, but PTE must be applied for by the patent owner within 60 days after FDA approval. Only one patent per product approval can receive a PTE, and it must claim the product itself, a method of using it, or a method of manufacturing it.
No. PTA has no statutory maximum. The total is A Delay + B Delay + C Delay, less any overlap between A and B and less applicant delay, so it depends on how long the USPTO took. PTE, by contrast, is capped at 5 years, and the total remaining term after the extension cannot exceed 14 years from the date of FDA approval.
Related guides
- How to Calculate Patent Term Extension (PTE)The step-by-step §156 formula: ½ testing phase + approval phase, the 5-year and 14-year caps, and a worked example.
- When Does a Patent Expire? A Complete Guide to Patent TermComprehensive overview of the 20-year term, PTA, terminal disclaimers, and maintenance fees.
- How Terminal Disclaimers Affect Patent ExpirationExplains how a terminal disclaimer caps patent term to match a related patent.
- How to Calculate Patent Expiration for Continuations and DivisionalsHow continuation and divisional filings tie patent term back to the parent application.
- How to Find the Earliest Effective Filing Date for Patent TermStep-by-step guide to tracing the continuity chain and identifying the correct filing date for term.
- Applicant Delay and PTA ReductionsHow 37 CFR 1.704 applicant delay reduces PTA, including the 3-month reply rule and IDS safe harbor.
- How to Verify and Challenge USPTO PTA CalculationsStep-by-step guide to checking the USPTO’s PTA math and requesting corrections under 37 CFR 1.705(b).
- RCEs and Patent Term: The B-Delay Trade-OffHow filing an RCE excludes time from B-Delay and the strategic trade-offs with appeal.
- Double Patenting, PTA, and Patent FamiliesHow obviousness-type double patenting interacts with PTA after Cellect and Allergan.
- Maintenance Fees and Patent ExpirationThe 3.5/7.5/11.5-year deadlines, grace periods, revival, and intervening rights.
Open it as a compiled matter in your own AI.
Give PatentReply a published U.S. application number and it compiles the prosecution record for Claude, ChatGPT, Grok, or another supported AI client: claims and their amendment history, Office Actions, cited references, and prosecution events, kept as one connected record.
One new published application a month is free. The first compile takes a few minutes.
Strategy and filing changes require your approval.